Literature DB >> 28258691

Viewing Siglecs through the lens of tumor immunology.

Isabella Fraschilla1, Shiv Pillai1.   

Abstract

Many Siglecs function as inhibitory receptors on innate and adaptive immune cells and may contribute to the attenuation of immune responses to n class="Disease">tumors. Siglec 9 on neutrophils and Siglec 7 on NK cells are prominent examples of inhibitory Siglecs that can potentially dampen anti-tumor immunity. CD169 is a Siglec that may function as an adhesion molecule and a facilitator of the recognition and internalization of sialic acid decorated apoptotic bodies and exosomes derived from tumors. It can potentially contribute to both the attenuation as well as the facilitation of anti-tumor immunity. Siglecs have been best studied in the tumor context in animal models of cancer. Modulators of Siglec function are likely to be developed and investigated clinically in a cancer context over the next few years.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Siglec; cancer/tumor immunology; hypersialylation; immune evasion; immune regulation; inhibitory receptor; sialic acid

Mesh:

Substances:

Year:  2017        PMID: 28258691      PMCID: PMC5860639          DOI: 10.1111/imr.12526

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  131 in total

1.  Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.

Authors:  Kevin Lock; Jiquan Zhang; Jinhua Lu; Szu Hee Lee; Paul R Crocker
Journal:  Immunobiology       Date:  2004       Impact factor: 3.144

2.  Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.

Authors:  Dzung H Nguyen; Edward D Ball; Ajit Varki
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

3.  Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9.

Authors:  Mariko Ohta; Akiko Ishida; Munetoyo Toda; Kaoru Akita; Mizue Inoue; Keishi Yamashita; Masashi Watanabe; Takeomi Murata; Taichi Usui; Hiroshi Nakada
Journal:  Biochem Biophys Res Commun       Date:  2010-10-29       Impact factor: 3.575

4.  Hyperresponsive B cells in CD22-deficient mice.

Authors:  T L O'Keefe; G T Williams; S L Davies; M S Neuberger
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

Review 5.  Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.

Authors:  S Hakomori
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

6.  Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

Authors:  Shuhei Tanida; Kaoru Akita; Akiko Ishida; Yugo Mori; Munetoyo Toda; Mizue Inoue; Mariko Ohta; Masakazu Yashiro; Tetsuji Sawada; Kosei Hirakawa; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

7.  Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.

Authors:  Maurizio Perdicchio; Juan M Ilarregui; Marleen I Verstege; Lenneke A M Cornelissen; Sjoerd T T Schetters; Steef Engels; Martino Ambrosini; Hakan Kalay; Henrike Veninga; Joke M M den Haan; Lisette A van Berkel; Janneke N Samsom; Paul R Crocker; Tim Sparwasser; Luciana Berod; Juan J Garcia-Vallejo; Yvette van Kooyk; Wendy W J Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-03       Impact factor: 11.205

8.  Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169.

Authors:  Weihsu C Chen; Norihito Kawasaki; Corwin M Nycholat; Shoufa Han; Julie Pilotte; Paul R Crocker; James C Paulson
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

9.  Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells.

Authors:  M Falco; R Biassoni; C Bottino; M Vitale; S Sivori; R Augugliaro; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

10.  Sialoadhesin on macrophages: its identification as a lymphocyte adhesion molecule.

Authors:  T K van den Berg; J J Brevé; J G Damoiseaux; E A Döpp; S Kelm; P R Crocker; C D Dijkstra; G Kraal
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

View more
  41 in total

Review 1.  How galectins have become multifunctional proteins.

Authors:  Gabriel García Caballero; Herbert Kaltner; Tanja J Kutzner; Anna-Kristin Ludwig; Joachim C Manning; Sebastian Schmidt; Fred Sinowatz; Hans-Joachim Gabius
Journal:  Histol Histopathol       Date:  2020-01-10       Impact factor: 2.303

2.  The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.

Authors:  Przemyslaw Wielgat; Robert Czarnomysy; Emil Trofimiuk; Halina Car
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

3.  Introduction to checkpoint inhibitors and cancer immunotherapy.

Authors:  Arlene H Sharpe
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.

Authors:  Stacy A Malaker; Kayvon Pedram; Michael J Ferracane; Barbara A Bensing; Venkatesh Krishnan; Christian Pett; Jin Yu; Elliot C Woods; Jessica R Kramer; Ulrika Westerlind; Oliver Dorigo; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-25       Impact factor: 11.205

Review 5.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

6.  Molecular Profiling of Exceptional Responders to Cancer Therapy.

Authors:  Marijo Bilusic; Daniel Girardi; Yan Zhou; Kyungsuk Jung; Jianming Pei; Michael Slifker; Qingrong Chen; Daoud Meerzaman; Katherine Alpaugh; Denise Young; Douglas Flieder; Phillip Gray; Elizabeth Plimack
Journal:  Oncologist       Date:  2020-11-28

7.  Siglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells.

Authors:  Jerry J Fong; Chih-Ming Tsai; Sudeshna Saha; Victor Nizet; Ajit Varki; Jack D Bui
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-25       Impact factor: 11.205

8.  Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma.

Authors:  Jing Liao; Dan-Ni Zeng; Jin-Zhu Li; Qiao-Min Hua; Chun-Xia Huang; Jing Xu; Chong Wu; Limin Zheng; Wei-Ping Wen; Yan Wu
Journal:  Mol Ther       Date:  2021-09-24       Impact factor: 11.454

9.  Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.

Authors:  Nan Xiao; Xiaodong Zhu; Kangshuai Li; Yifan Chen; Xuefeng Liu; Bin Xu; Ming Lei; Jiejie Xu; Hui-Chuan Sun
Journal:  Exp Hematol Oncol       Date:  2021-06-10

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.